Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3509552 | 1.00 | ATM (0.44) | ATMHSD17B10USP2SMN1; SMN2CNR2 | |
| SCHEMBL3509553 | 1.00 | ATM (0.44) | ATMHSD17B10USP2SMN1; SMN2CNR2 | |
| SCHEMBL23260724 | 0.88 | ATM (0.43) | ATMHSD17B10USP2SMN1; SMN2CHRM2 | |
| SCHEMBL202300 | 0.85 | ACE (0.48) | ATMHSD17B10USP2SMN1; SMN2CHRM2 | |
| SCHEMBL202301 | 0.85 | ACE (0.48) | ATMHSD17B10USP2SMN1; SMN2CHRM2 | |
| SCHEMBL26077743 | 0.85 | ATM (0.45) | ATMHSD17B10USP2SMN1; SMN2CHRM2 | |
| SCHEMBL14237836 | 0.85 | ATM (0.45) | ATMHSD17B10USP2SMN1; SMN2CHRM2 | |
| SCHEMBL16187224 | 0.85 | ATM (0.45) | ATMHSD17B10USP2SMN1; SMN2CHRM2 | |
| SCHEMBL1022969 | 0.85 | ACE (0.48) | ATMHSD17B10USP2SMN1; SMN2CHRM2 | |
| SCHEMBL10215588 | 0.84 | HSD17B10 (0.40) | ATMHSD17B10USP2SMN1; SMN2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070899-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2026-03-12 | — | — | US | disclosed |
| US-20250368637-A1 | SOLID-STATE FORMS OF N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-6-MORPHOLINOQUINOLINE-4-CARBOXAMIDE | ASTRAZENECA AB (SE) | 2025-12-04 | — | — | US | disclosed |
| US-12473285-B2 | DCN-1 modulating compounds and methods of use thereof | CELLARITY, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250257063-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-08-14 | — | — | US | disclosed |
| US-20250163057-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-05-22 | — | — | US | disclosed |
| CN-119585266-A | Solid state forms of N- (2- (4-cyanothiazolidin-3-yl) -2-oxoethyl) -6-morpholinoquinoline-4-carboxamide | 阿斯利康(瑞典)有限公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119562951-A | N- (2- (4-cyanothiazolidin-3-yl) -2-oxoethyl) -quinoline-4-carboxamide | 阿斯利康(瑞典)有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20240101549-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2024-03-28 | — | — | US | disclosed |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | ASTRAZENECA (SE) | 2024-01-02 | — | — | US | disclosed |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | ASTRAZENECA (SE) | 2024-01-02 | — | — | US | disclosed |
| EP-1450794-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) INHIBITORS AS ANTI-DIABETIC AGENTS | FERRING B.V. (NL) | 2004-09-01 | — | — | EP | disclosed |
| US-20040082497-A1 | Inhibitors of dipeptidyl peptidase IV | FERRING BV (NL) | 2004-04-29 | — | — | US | disclosed |
| US-20030216450-A1 | Inhibitors of dipeptidyl peptidase IV | FERRING BV (NL) | 2003-11-20 | — | — | US | disclosed |
| CN-1426409-A | Inhibitors of dipeptidyl peptidase IV | FERRING BV (NL) | 2003-06-25 | — | — | CN | disclosed |
| CN-1426395-A | Dipeptidyl peptidase-IV inhibitors | FERRING BV (NL) | 2003-06-25 | — | — | CN | disclosed |
| WO-2003035067-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV (DP-IV) INHIBITORS AS ANTI-DIABETIC AGENTS | FERRING B.V. (NL) | 2003-05-01 | — | — | WO | disclosed |
| EP-1282600-A1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | Ferring BV (NL) | 2003-02-12 | — | — | EP | disclosed |
| EP-1280797-A1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | FERRING B.V. (NL) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001081304-A1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | FERRING BV (NL) | 2001-11-01 | — | — | WO | disclosed |
| WO-2001081337-A1 | INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | FERRING B.V. (NL) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473285-B2 | DCN-1 modulating compounds and methods of use thereof | DCUN1D1, DCUN1D2, DCUN1D4 | ATM 4447/4885HSD17B10 2353/4885USP2 4383/4885 |
| US-20030216450-A1 | Inhibitors of dipeptidyl peptidase IV | DPP4, DPP7, DPP8 | ATM 4859/4885HSD17B10 816/4885USP2 1656/4885 |
| US-20040082497-A1 | Inhibitors of dipeptidyl peptidase IV | DPP4, DPP7, DPP3 | ATM 4877/4885HSD17B10 290/4885USP2 901/4885 |
| US-20250163057-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | ATM 4447/4885HSD17B10 2353/4885USP2 4383/4885 |
| US-20250368637-A1 | SOLID-STATE FORMS OF N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-6-MORPHOLINOQUINOLINE-4-CARBOXAMIDE | FAP, FIBP, DNPEP | ATM 3109/4885HSD17B10 4631/4885USP2 1217/4885 |
| US-20260070899-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | FAP, CTRL, CTSC | ATM 4415/4885HSD17B10 3616/4885USP2 1352/4885 |
| US-20240101549-A1 | N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOETHYL)-QUINOLINE-4-CARBOXAMIDES | FAP, PREP, CTRL | ATM 4050/4885HSD17B10 4763/4885USP2 1190/4885 |
| US-20250257063-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | ATM 4447/4885HSD17B10 2353/4885USP2 4383/4885 |
| US-11858924-B2 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides | FAP, PREP, CTRL | ATM 4050/4885HSD17B10 4763/4885USP2 1190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.